Skip to content

Relationship Between D2 Receptors SPECT and the Apomorphine Test in Patients With OH Dependence (ALC-DRD2-APO)

Relationship Between D2 Receptors SPECT and the Apomorphine Test in Patients With OH Dependence: Predictive Value for Relapse

Status
UNKNOWN
Phases
Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00437177
Acronym
ALC-DRD2-APO
Enrollment
50
Registered
2007-02-19
Start date
2007-01-31
Completion date
2010-06-30
Last updated
2009-04-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Alcoholism

Keywords

alcoholism, apomorphine, iodobenzamide, imaging, spect, relapse

Brief summary

OH dependence is associated with DA receptor changes. Both, the apomorphine test and the D2Rec SPECt are usefull for monitoring DA receptor status. We aimed at studying whether DA receptor hypofunction, assessed by means of the apomorphine test and the D2Rec SPECT, is a marker of relapse in detoxified OH dependents patients.

Interventions

Apomorphine 0.05 mg/kg subcutaneously at hospital admission and at discharge. Abstinent participants at 3 months will receive a third dose.

DRUG[(123)I] iodobenzamide

\[(123)I\] iodobenzamide 185 MBq I.V., at discharge.

Sponsors

Hospital Universitari Vall d'Hebron Research Institute
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
BASIC_SCIENCE
Masking
NONE

Eligibility

Sex/Gender
MALE
Age
25 Years to 60 Years
Healthy volunteers
No

Inclusion criteria

* alcohol dependence * alcohol dependence length at least 8 years. * male * age 25 - 60 years

Exclusion criteria

* other drug dependence (except nicotine dependence) * another major axis I psychiatric diagnosis * comorbid neurological disorder * comorbid cardiovascular disorder * comorbid metabolic disorder * brain injury * apomorphine allergy * iode allergy * diazepam allergy

Design outcomes

Primary

MeasureTime frame
To detertmine the agreement rate of the dopaminergic sensibility assessed by two different techiniques: the apomorphine test and and IBZM SPECT.3 months

Countries

Spain

Contacts

Primary ContactMiquel Casas, Prof.
mcasas@vhebron.net
Backup ContactXavier Castells, Prof
xcc@icf.uab.cat

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026